Stock RGEN REPLIGEN CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Repligen Corporation

Equities

RGEN

US7599161095

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
120.1 USD -2.58% Intraday chart for Repligen Corporation -2.44% -33.18%
Jun. 26 Deutsche Bank Upgrades Repligen to Buy From Hold, Cuts Price Target to $155 From $180 MT
Jun. 24 RBC Cuts Price Target on Repligen to $190 From $221, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Deutsche Bank Upgrades Repligen to Buy From Hold, Cuts Price Target to $155 From $180
MT
RBC Cuts Price Target on Repligen to $190 From $221, Maintains Outperform Rating
MT
Guggenheim Initiates Repligen With Neutral Rating
MT
Broadcom, Korn Ferry rise; Signet Jewelers, Repligen fall, Thursday, 6/13/2024
AQ
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
Repligen Names Olivier Loeillot CEO; Tony Hunt to Become Executive Chair
MT
Repligen Announces CEO Transition Plan
AQ
Repligen Corporation Announces Management Changes, Effective September 1, 2024
CI
Repligen Corporation Announces CEO Changes, Effective September 1, 2024
CI
Transcript : Repligen Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 11:30 AM
Transcript : Repligen Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 12:00 PM
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
CI
Transcript : Repligen Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 08:40 AM
Repligen Insider Sold Shares Worth $3,377,283, According to a Recent SEC Filing
MT
Repligen Corporation to Present at Upcoming June Investor Conferences
AQ
Repligen : Investor Presentation May 2024 Presentation
PU
Transcript : Repligen Corporation Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
Repligen Corporation to Present at Upcoming May Investor Conferences
AQ
UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating
MT
Repligen's Q1 Adjusted Earnings, Revenue Fall
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGEN Stock
  4. News Repligen Corporation